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Racecadotril is a guideline-recommended treatment to alleviate symptoms of acute 
diarrhea. A systematic review of randomized studies was performed comparing efficacy 
and safety of treatment with racecadotril to that with placebo or active treatments in 
adults. In five double-blind studies, racecadotril and placebo had comparable tolera-
bility, but racecadotril was more effective. This was consistent across multiple efficacy 
parameters including duration of diarrhea, number of diarrheic stools, abdominal pain, 
and meteorism; it was also consistent across countries in Africa, Asia, and Europe. In six 
randomized studies in outpatients comparing racecadotril to loperamide, resolution of 
symptoms occurred with similar speed and efficacy; however, racecadotril treatment was 
associated with less rebound constipation and less abdominal discomfort. The seventh 
comparative study performed in geriatric nursing home residents reported a superior 
efficacy of racecadotril. In direct comparison with Saccharomyces boulardii treatment, 
racecadotril exhibited similar tolerability but was more efficacious. One study compared 
racecadotril to octreotide in patients with acute diarrhea requiring hospitalization, rehy-
dration, and antibiotic treatment; in this cohort, octreotide was more efficacious than 
racecadotril. In conclusion, in adults with acute diarrhea, racecadotril is more efficacious 
than placebo or S. boulardii, similarly efficacious as loperamide and, in patients with 
moderate to severe disease as add-on to antibiotics, less than octreotide. The tolerability 
of racecadotril is similar to that of placebo or S. boulardii and better than that of lop-
eramide, particularly with regard to risk of rebound constipation. Taken together, these 
data demonstrate that racecadotril is a suitable treatment to alleviate symptoms of acute 
diarrhea in adults.
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iNTRODUCTiON
Acute diarrhea causes millions of deaths each year. Most of these occur in children in developing 
countries, particularly in infants. However, diarrhea is also a significant medical problem in adults 
and in industrialized countries (1), where it continues to be an important cause of morbidity, health-
care utilization, and lost working days (2). For instance, an estimated 375 million episodes of acute 
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diarrhea occur annually in the US, leading to 900,000 hospitali-
zations and causing 6,000 deaths (3, 4). Infectious enteritis with 
mandatory reporting to competent authorities also remains high 
in other industrialized countries such as Germany (5). Infections 
with bacteria, viruses, and parasites are the most important cause 
of acute diarrhea; while bacteria are the leading cause of acute 
diarrhea in the developing countries, viruses are its most frequent 
cause in industrialized countries (2). Transmission occurs in most 
cases via contaminated water or foodborne (6). Widespread use 
of broad-spectrum antibiotics and increased foreign travel may 
further increase the incidence of acute diarrhea in adults from 
industrialized countries.
As dehydration is the most frequent cause of death in acute 
diarrhea, oral rehydration therapy is the most important compo-
nent of treatment. Its increasing use has been associated with a 
major reduction in deaths due to acute diarrhea (2). While infec-
tious acute diarrhea tends to be self-limiting in otherwise healthy 
people, it is not only unpleasant but also has societal impact such 
as lost working days (3). Moreover, even in adults in industrial-
ized countries, diarrhea may lead to death due to visceral failure 
secondary to dehydration, particularly in the elderly (4).
Therefore, several medications have been developed to 
alleviate diarrhea symptoms and fasten time to resolution, 
among which loperamide is used most often. Loperamide is a 
peripherally acting μ-opiate receptor agonist that has extensively 
been studied in the treatment of acute diarrhea and is on the 
List of Essential Medications of the World Health Organization. 
While clearly effective, loperamide has a number of limitations. 
First, use of loperamide in the treatment of diarrhea can lead to 
secondary constipation (7). Second, such constipation may lead 
to risk of bacterial retention, which is undesirable with toxin-
producing bacteria strains (8). Therefore, the US Food and Drug 
Administration considers loperamide contraindicated in patients 
with bacterial enterocolitis caused by invasive microorganisms 
including Salmonella, Shigella, and Campylobacter species and 
those with pseudomembranous colitis associated with use of 
broad-spectrum antibiotics (9). Third, loperamide has a consid-
erable potential for drug–drug interactions as it is metabolized by 
cytochrome P450 (CYP) 2C8 and 3A4. Accordingly, concomitant 
use of drugs inhibiting these enzymes can markedly increase lop-
eramide plasma concentrations (9). Moreover, the limited central 
effects of loperamide are largely driven by it being a substrate 
for P-glycoprotein. Therefore, P-glycoprotein inhibitors can not 
only increase loperamide plasma levels (9) but also enhance its 
access to the brain (10). Based on these drug–drug interactions 
and also on cases of overdosing and abuse, the US Food and Drug 
Administration has recently warned about a risk of serious heart 
problems when using loperamide (11). While loperamide is gen-
erally deemed sufficiently safe for self-medication (2), pharmacy 
customers may insufficiently understand the relevance of such 
interactions and heed corresponding advice from the pharmacist 
or package insert.
Probiotics, particularly Lactobacillus rhamnosus GG and 
Saccharomyces boulardii, have also repeatedly been studied for 
the treatment of acute infectious diarrhea. While several guide-
lines propagate their use, particularly in children, the National 
Institute for Health and Clinical Excellence in the UK and the 
Center for Disease Control in the US have concluded that they 
are not recommended in this indication (12). While the UK 
National Institute for Health and Clinical Excellence evaluation 
has acknowledged the superiority of some probiotics relative to 
placebo in the treatment of acute diarrhea in children, it did not 
recommend their use because of limitations in the methodology 
of the underlying studies (13). The US Center for Disease Control 
mainly criticized that available studies had small sample sizes, 
raising the possibility that similarly small studies with negative 
outcomes may not have been reported (14). Only little placebo-
controlled data are available evaluating the efficacy of probiotics 
in the treatment of acute diarrhea in adults. Similarly, various 
plant extracts based on traditional medicines have been tested 
in animal models of acute diarrhea, for instance, of Calea zacat-
echichi (15), but little evidence from controlled clinical studies in 
adults exists.
Somatostatin decreases gastrointestinal motility and intestinal 
fluid and electrolyte transport but has a short half-life and exhibits 
tachyphylaxis. Analogs of somatostatin, such as octreotide, may 
have a longer duration of action. Somatostatin and octreotide 
regulate mediators of diarrhea at the cellular level and have been 
tested with favorable results in some types of diarrhea, mostly 
in patients with AIDS or undergoing cancer chemotherapy (16). 
However, neither somatostatin nor octreotide has been approved 
for the indication of acute diarrhea in any major country.
Racecadotril, also known as acetorphan, is an alternative 
medical option for the treatment of acute diarrhea (17–19). 
Racecadotril is a low potency inhibitor of neutral endopeptidase 
(NEP; EC 3.4.24.11, also known as enkephalinase). However, 
racecadotril is rapidly converted to thiorphan in vitro and in vivo, 
which is a much more potent NEP inhibitor (20). Thiorphan has 
two stereoisomers, the S-enantiomer being referred to as ecadotril 
or sinorphan and the R-isomer as retorphan or dexecadotril (21). 
Ecadotril may be somewhat more potent than retorphan, but the 
difference appears small as compared to the prodrug racecadotril 
and its alternative metabolite acetyl-thiorphan. Recently, we have 
comprehensively reviewed the pharmacological profile of racec-
adotril, including its pharmacokinetics (22). Related to diarrhea 
treatment, the most important effect of racecadotril is inhibition 
of the degradation of enkephalins, which in turn have potent 
antisecretory activity but only little effect on motility in the gut 
(23). While racecadotril did not inhibit basal secretion in canine 
jejunum, it inhibited cholera toxin-induced secretion (24). It also 
inhibited cholera toxin-induced secretion in human jejunum (25) 
and rotavirus-induced secretion in Caco-2 cells (26). However, in 
contrast to loperamide, racecadotril did not affect gastrointestinal 
transit time in rats or mice (27) or in healthy human volunteers 
(28, 29). Accordingly, loperamide increased Escherichia coli con-
tent in proximal jejunum and decreased it in stool in newborn 
piglets, whereas racecadotril did not alter content of the infec-
tious agent in jejunum or stool (30). Based on this mechanism 
of action, racecadotril has proven effective in castor oil-induced 
diarrhea in rats (27) and in healthy human volunteers (31). 
Accordingly, racecadotril is a guideline-recommended treatment 
of acute diarrhea (2, 32, 33).
Against this background, we have summarized placebo- 
controlled studies of racecadotril in the treatment of acute 
FigURe 1 | Flow chart depicting selection of studies included in 
analysis. In addition to the two databases, PubMed and Scopus, reference 
lists from two reviews by Coffin et al. (34) and Vetel et al. (35) were extracted. 
Numbers indicate number of studies from a given source or with the 
indicated comparator treatment.
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diarrhea  followed by a comprehensive discussion of direct 
 comparative studies between racecadotril and other medical 
options in the treatment of acute diarrhea in adult patients.
MeTHODS
Our analysis is primarily based on dedicated literature searches 
performed in November 2015 in PubMed and Scopus for the key 
word combination “racecadotril” and “diarrhea.” Studies were 
included if they reported direct comparative data of racecadotril 
and placebo or other treatments of diarrhea in adults; studies 
in children were not considered. Reference lists of retrieved 
articles were analyzed for additional publications. There were no 
language limitations of the search; articles published in English, 
French, or German were directly analyzed by the authors, one 
publication in Portuguese was translated into English by a profes-
sional translator, and one in Chinese was extracted by a native 
speaker colleague.
While our manuscript was in preparation, we became aware 
of an individual patient-based meta-analysis of four placebo-
controlled studies (34) and a systematic review and meta-analysis 
on the efficacy of racecadotril in the treatment of acute diarrhea 
in adults (35). Both provide important insight into the efficacy 
of racecadotril in adults with acute diarrhea, and their reference 
lists were scanned to retrieve studies not listed in PubMed or 
Scopus (Figure  1). However, we decided to carry on with the 
present project for two reasons. First, particularly based on the 
availability of racecadotril as over-the-counter medication in 
many countries, we feel that a combined analysis of efficacy and 
tolerability of racecadotril, particularly in comparison to other 
treatment options, is required for a clinically meaningful under-
standing of the different profile of treatment options. Second, 
Vetel et al. have focused on treatment efficacy defined as dura-
tion of diarrhea, i.e., time from treatment onset to last unformed 
stool. While most studies have reported on duration of diarrhea, 
this has not always been the primary endpoint (36). Moreover, 
other efficacy parameters, such as meteorism, pain, and nausea, 
may also be relevant to patients but have not been covered in 
the analysis by Vetel et al. (35). However, similar to Vetel et al., 
we have defined studies as out of scope which relate to diarrhea 
associated with cancer chemotherapy (37–41), cholera (42), 
or AIDS (43, 44), as these may have different pathologies and 
hence treatment responsiveness as compared with acute diarrhea. 
Moreover, studies comparing multiple doses and/or formulations 
of racecadotril but not including a placebo or active treatment 
comparator arm have also been considered as out of scope. The 
flowchart in Figure 1 depicts how studies were selected for inclu-
sion in the present analysis; those studies are listed in Table 1. 
The present article concomitantly describes error bars as SE or as 
SD, depending on the choice of the investigators in their original 
reports.
PLACeBO-CONTROLLeD STUDieS 
ON RACeCADOTRiL iN ADULTS
Five double-blind, randomized studies have explored the efficacy 
and tolerability of racecadotril relative to placebo in acute 
diarrhea in adults. An initial multi-center dose-ranging study 
performed in France compared racecadotril capsules of 30, 100, 
and 300 mg to placebo, each administered thrice daily prior to a 
meal (45). The main inclusion criterion was diarrhea lasting not 
more than 5 days (mean 1.5 days) with at least three unformed 
stools within the past 24 h (mean 6). Key exclusion criteria were 
chronic diarrhea of any cause, other complaints that may cause 
repeated or chronic diarrhea, alternating bouts of diarrhea and 
constipation, iatrogenic diarrhea, and concomitant diseases that 
might affect vital signs. Treatment lasted until the occurrence of 
the first formed stool or a period of 12 h without any stools but 
could not exceed 10 days. The primary efficacy endpoint was time 
to cure; secondary efficacy endpoints were self-assessed number 
and appearance of stools, percentage of patients cured and 
concomitant symptoms during consultations. Safety endpoints 
were based on clinical examination, reported side effects, and 
standard laboratory tests. Samples sizes were 49–55 per group, 
and most patients had negative stool cultures. The mean times to 
disappearance of loose or liquid stools were 72.0, 68.4, 69.6, and 
65.0 h in the placebo, 30, 100, and 300 mg racecadotril groups, 
respectively (not significantly different). Cure rates were 90–93% 
across all treatment groups. Three adverse events were reported 
in the placebo group (3/49; headache, nausea, cystitis) and 5 in 
the combined racecadotril groups [5/164; nausea (2 patients), 
meteorism, dizziness, and bad taste]. Number of loose stools was 
2.7 vs. 2.1 (P = 0.06) in the first 9 h and 8.6 vs. 7.1 (P = 0.03) 
in the first 60  h with no evident dose-dependency among the 
racecadotril groups. Based on these findings, all subsequent 
placebo-controlled studies have focused on the 100  mg dose 
of racecadotril.
Another multi-center, double-blind study also performed 
in France has used comparable inclusion and exclusion criteria 
and randomized 198 patients (18–89  years) to receive 100  mg 
racecadotril or placebo, two capsules at start of treatment and 
one after each unformed stool, until resolution of diarrhea (31). 
TABLe 1 | Studies included in the present analysis with corresponding sample size.
Comparator Reference Sample  
size per arm
Reported efficacy parameters
Placebo-controlled studies on racecadotril
Placebo Vetel et al. (45) 54–59 Duration of diarrhea (P); number and appearance of stools; percentage of patients cured; 
concomitant symptoms
Placebo Baumer et al. (31) 96–102 Duration of diarrhea (P); percentage of patients cured; Kaplan–Meier analysis of presence of diarrhea; 
reduction of anal burning, spontaneous abdominal pain, nausea, weight loss, pain on abdominal 
palpation, and meteorism; global efficacy
Placebo Hamza et al. (36) 32–38 Stool weight on first day of treatment; number of loose stools; pain on abdominal palpation; anal 
burning; painful anal contraction; spontaneous abdominal pain; abdominal distension; nausea; 
vomiting; loss of appetite
Placebo Coffin and  
Rampal (46)
86–87 Number of diarrheic stools until day 5 (P) and on first day of treatment; duration of diarrhea; 
associated symptom index; well-being index; global index
Standard  
treatment
Yao and  
Xi (47)
54–55 Duration of diarrhea (P); treatment duration; percentage of patients cured
Actively controlled studies on racecadotril
Loperamide Roge et al. (48) 32–37 Duration of diarrhea (P); cumulative recovery on day 2 (P); abdominal pain; abdominal distension
Loperamide Vetel et al. (49) 75–82 Number of stools until recovery (P); time to cure; physician’s global evaluation; asthenia; abdominal 
distension; anorexia; pain on abdominal palpation; spontaneous abdominal pain; nausea; anal 
burning; vomiting
Loperamide Prado and Global 
Adult Racecadotril 
Study Group (50)
472–473 Duration of diarrhea (P); recovery rate after 72 h; overall clinical success; duration of abdominal pain 
and of abdominal distension
Loperamide Wang et al. (51) 31 Duration of diarrhea, abdominal pain, and abdominal distension; improvement rate of anal burn and 
nausea; physician-determined overall clinical success
Loperamide Hu and Sun (52) 111–112 Duration of diarrhea in Kaplan–Meier analysis (P); resolution rate at 24, 48, and 72 h; percentage 
of patients reporting resolution of spontaneous abdominal pain, pain on abdominal palpation, 
abdominal distension, anorexia, nausea, and anal burning
Loperamide Coulden et al. (53) 60 Duration of diarrhea (P); time to resolution of spontaneous abdominal pain and abdominal distension; 
prevalence of spontaneous abdominal pain, pain on abdominal palpation, abdominal distension, 
anorexia, nausea, and anal burning
Loperamide Galleli et al. (54) 30–31 Number of diarrhea episodes; duration of abdominal pain and diarrhea; stool weight until recovery
Saccharomyces 
boulardii
Moraes et al. (55) 161–175 Clinical success as judged by investigator; duration of diarrhea; number of bowel movements until 
recovery; prevalence of spontaneous abdominal pain, pain on abdominal palpation, abdominal 
distension, anorexia, nausea, and anal burning on day 2; Kaplan–Meier analysis of probability of cure
Octreotide Mehta et al. (56) 50 Daily number of stools until recovery (P); daily quantity of stools; required volume of fluid substitution
See main text and references for details.
(P), primary endpoint; where not stated, no efficacy parameter has been reported as primary endpoint.
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Mean duration of diarrhea prior to start of treatment was 1.7 and 
1.6 days, and mean number of loose stools in the preceding 24 h 
was 5.3 and 4.9, respectively. Five patients, all in the placebo group, 
prematurely discontinued the study because diarrhea worsened 
or failed to improve. Moreover, at study-end visit (10–14  days 
after initiation of treatment), 30 patients reported the continued 
presence of unformed stools. These 35 patients were excluded 
from the analysis of the primary endpoint, time to cure (7.4 vs. 
23.5% in the racecadotril and placebo group, respectively). The 
remaining patients reported a duration of diarrhea during treat-
ment of 3.4 ± 0.1 days in the racecadotril and 4.4 ± 0.2 days in 
the placebo group (P = 0.001). As fewer patients on racecadotril 
failed to achieve cure during the observation period, the differ-
ence between treatments would have been larger in an intention-
to-treat analysis of all participants. Accordingly, a Kaplan–Meier 
type of analysis for probability of presence of diarrhea, including 
also the 35 patients without cure, also confirmed superiority 
of racecadotril over placebo (P <  0.001). Thus, the probability 
of reporting cure on day 4 was 75 ±  5% in the racecadotril as 
compared with 37 ± 5% in the placebo group. As compared to 
placebo, racecadotril also caused a significantly greater reduction 
of anal burning, spontaneous abdominal pain, nausea, weight 
loss, pain on abdominal palpation, and meteorism. Global effi-
cacy rating by the physician on a visual analog scale of 1–100 was 
83 ± 2 vs. 61 ± 3, respectively, and by the patient 82 ± 2 vs. 62 ± 3, 
respectively (P < 0.001). Approximately 16 (16.8%) vs. 18 (18.4%) 
of patients on racecadotril as compared to placebo reported a total 
number of 35 vs. 36 adverse events (n.s.). These included nausea, 
thirst, dizziness, constipation, and headache and were largely of 
mild to moderate intensity in both groups. Tolerability rating on 
a visual analog scale by physicians was 89 ± 2 vs. 89 ± 1 and by 
patients 93 ± 2 vs. 87 ± 2 (n.s.).
The third double-blind study in adults with acute diarrhea 
performed in Tunisia has used similar key inclusion and exclu-
sion criteria, and randomized 71 patients to receive 100  mg 
racecadotril or placebo thrice daily until diarrhea had ended for 
a maximum of six treatment days (36). In contrast to the above 
studies, the primary efficacy endpoint was accumulated stool 
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weight during the first day of treatment. Causative microorgan-
isms were identified in only five patients. Mean stool weight 
during the first day of treatment was 355 ± 35 g with racecadotril 
treatment as compared to 499 ±  46  g with placebo treatment 
(P = 0.025), corresponding to a 28.9% reduction in stool weight 
by racecadotril treatment. Number of loose stools in the 24  h 
prior to start of treatment was 6.4 ± 0.5 vs. 6.3 ± 0.4, and after 
1 day of treatment this had declined to 4.3 ±  0.4 vs. 5.4 ±  0.4 
in the racecadotril and placebo groups, respectively (P = 0.027). 
On day 2, 15.6% of patients receiving racecadotril passed at least 
one formed stool as compared to 5.3% in the placebo group. 
While pain on abdominal palpation on day 4 was similar in both 
groups (10.7 vs. 9.7%), patients receiving racecadotril reported 
less anal burning (18.2 vs. 25%), painful anal contraction (0 vs. 
12.5%), spontaneous abdominal pain (22.6 vs. 27.3%), abdominal 
distension (5.6 vs. 18.2%), nausea (4.8 vs. 16.7%), vomiting (0 
vs. 12.5%), and loss of appetite (15.4 vs. 18.8%). Adverse events 
were reported by 3.1 and 5.3% in the racecadotril and placebo 
group. Physician’s global tolerability assessment on a 1–100 scale 
was 96.1 ±  4.2 vs. 94.2 ±  16.5, respectively.
The fourth double-blind, double dummy study performed 
in France in adults with acute diarrhea has also used similar 
key inclusion and exclusion criteria except that maximum prior 
duration of diarrhea was limited to 3 days (46). This study has 
randomized 259 patients to receive one of the three treatments: 
racecadotril 100  mg capsules, dexecadotril 75  mg tablets, or 
placebo thrice daily until recovery (12 h without stools or two 
consecutive normal stools) for a maximum of 5 days. Of note, 
the primary analysis of this study compared dexecadotril to 
either racecadotril or placebo; therefore, no statistical analysis 
of the comparison of efficacy of racecadotril and placebo was 
reported. A total of 22 patients prematurely discontinued the 
study: 6 in the racecadotril group (3 due to lack of efficacy, 3 
due to unauthorized concomitant treatment before or during 
study), 6 in the dexecadotril group (4 due to lack of efficacy, 2 
due to adverse events), and 10 in the placebo group (5 due to 
lack of efficacy, 2 each due to concomitant disease and loss to 
follow-up, 1 due to poor compliance). The median number of 
diarrheic stools in the 24 h prior to start of treatment was 5–6. 
The primary efficacy endpoint was number of diarrheic stools 
from start of treatment until recovery or day 5; this was 5, 3, 
and 9 with racecadotril, dexecadotril, and placebo, respectively, in 
the intention-to-treat analysis. Upon adjustment for stool quality 
(normal = 0, loose = 1, watery = 2), median weighted number 
was 8, 4 and 15, respectively. Among the secondary endpoints, 
median duration of diarrhea was 30, 13, and 67 h, respectively. 
On day 5, 96.5, 94.2, and 82.8% of patients had recovered, 
respectively. The symptom indices were used as secondary 
efficacy endpoints. An associated symptom index consisting 
of spontaneous abdominal pain, bloating, gurgling, nausea, 
vomiting, loss of appetite, fever, and asthenia; each symptom 
was weighted by intensity from 0 (none) to 3 (important). A well-
being index based on impairment of daily activities, diet, sleep, 
and feeling of discomfort; each of the four was weighted from 
0 (none) to 3 (severe). A global index was calculated as the 
arithmetic mean of the associated symptom index, the well-being 
index, and the number of diarrheic stools divided by 3. While 
the associated symptom index and the well-being index were 
comparable across groups at baseline (1.0–1.3 and 1.2–1.3), the 
global index differed between groups with 10, 10.7, and 9.2 
in patients to receive racecadotril, dexecadotril, and placebo, 
respectively. At study end, the associated symptom index was 
1.7, 1.6, and 2.3, the well-being index 1.8, 1.4, and 2.3, and the 
global index 11.3, 8.8, and 17.8 in the racecadotril, dexecadotril, 
and placebo groups, respectively. A total of 25 patients reported 
a total of 34 adverse events during the study; this included 9 in 
the racecadotril, 14 in the dexecadotril, and 11 in the placebo 
group. Most of them were of mild to moderate intensity and 
had disappeared at study end.
These four placebo-controlled studies have been subject to 
two meta-analyses. One of them focused on the duration of 
diarrhea as efficacy and constipation as safety endpoint; it had 
also included a study in which the comparator arm was treated 
with the probiotic S. boulardii (35). In this analysis, the hazard 
ratio for a greater efficacy with racecadotril was 1.65 (confidence 
interval: 1.38–1.97). In contrast, the hazard ratio for safety was 
0.95 (0.24–3.68). The second meta-analysis included only the 
four placebo-controlled studies, was based on individual patient 
raw data, and included a wider range of efficacy endpoints (34). 
In contrast to some of the primary study reports, this analysis 
included all randomized patients on an intention-to-treat based, 
i.e., 669 patients. This included 59 and 56 receiving a 30- or 300-
mg dose, respectively, from the dose-ranging study (45), leaving 
282 patients receiving placebo and 272 patients receiving 100 mg 
racecadotril. At baseline, the latter two groups were well balanced 
with regard to age (41  years), gender (53.5% females), weight 
(66.6  kg), height (1.68 m), ethnicity (17.9% non-Caucasian), 
blood in stool (3.1%), watery stool aspect (91.0%), work inter-
ruption (41.0%), number of stools in last 24 h prior to treatment 
start (5.72), and additional symptoms including anal burning 
(57.2%), anal contractures (44.7%), spontaneous abdominal pain 
(91.6%), nausea (64.8%), vomiting (26.6%), appetite loss (77.7%), 
fatigue (82.7%), insomnia (50.0%), pain on palpitation (84.3%), 
and meteorism (76.2%). The primary efficacy parameter of the 
meta-analysis was duration of diarrhea. In a model adjusting 
for age, weight, and clinical global impression, the 100  mg 
racecadotril dose (identified to be the minimally effective dose) 
as compared to placebo exhibited a hazard ratio for benefit of 
1.85 [1.54; 2.23]. For analysis of overall symptom score, pain and 
nausea defined as number of symptoms on day 3 of treatment, 
the decrease from baseline depended on baseline severity and 
clinical global impression. When adjusting for these baseline 
variables, the hazard ratio for having the respective symptom 
with 100 mg racecadotril as compared to placebo was 0.73 [0.66; 
0.80] for overall symptom score, 0.41 [0.30; 0.56] for nausea and 
vomiting and 0.52 [0.42; 0.65] for abdominal pain. For responder 
analysis (recovery within 3 days after baseline), the hazard ratio 
was 1.602 [1.365; 1.881], for number of diarrheic stools 0.743 
[0.650; 0.849], and for sick leave duration 0.666 [0.528; 0.840].
The fifth study performed in China and not included in any 
of the previous meta-analyses or other reviews, randomized 109 
adults with acute diarrhea to receive standardized oral rehydra-
tion therapy or rehydration plus 100 mg racecadotril or placebo 
thrice daily (47). Prior to treatment, diarrhea existed for a mean 
FigURe 2 | Comparison of time to cure between rehydration treatment (“control”; n = 54) and rehydration treatment plus racecadotril 
(“racecadotril”; n = 55) in a randomized study. Of note, cure was observed in 39/54 patients (70.2%) in the control and 50/55 patients (90.9%) in the 
racecadotril group after 72 h of treatment. Data are means ± SD. *P < 0.05 vs. control. Drawn based on data published in Yao and Xi (47).
TABLe 2 | effect of racecadotril as compared to placebo or active treatment for the secondary symptoms meteorism/abdominal distension and 
abdominal pain.
Comparator Reference Meteorism/abdominal  
tension/bloating
Spontaneous  
abdominal pain
Control Racecadotril Control Racecadotril
Placebo-controlled studies on racecadotril
Placebo Vetel et al. (45) n.r. n.r. n.r. n.r.
Placebo Baumer et al. (31) 34.7% 18.3%* 20.5% 9.6%*
Placebo Hamza et al. (36) 18.2% 5.6% 27.3% 22.6%
Placebo Coffin and Rampal (46) n.r. n.r. n.r. n.r.
Standard treatment Yao and Xi (47) n.r. n.r. n.r. n.r.
Actively controlled studies on racecadotril
Loperamide Roge et al. (48) 50.0% 27.0%* 59.4% 40.5%*
Loperamide Vetel et al. (49) Comparable Comparable
Loperamide Prado and Global Adult  
Racecadotril Study Group (50)
24.4 h 5.4 h* 11.0 h 10.0 h
Loperamide Wang et al. (51) 12 h 12 h 14 h 16 h
Loperamide Galleli et al. (54) n.r. n.r. 28 h 14 h*
Loperamide Hu and Sun (52) 87% 88% 85% 91%
Loperamide Coulden et al. (53) 2 days 1 day 1 day 1 day
Saccharomyces boulardii Moraes et al. (55) 6.21% 6.29% 12.42% 6.86%
Octreotide Mehta et al. (56) n.r. n.r. n.r. n.r.
Data are percentage of patients reporting a given symptom during treatment or time (hours or days presented as mean or median) until resolution. Note that symptom assessment 
during treatment was performed on different treatment days in the various studies; moreover, some studies reported graphical rather than quantitative data (49). n.r., not reported; 
*P < 0.05 vs. control. In an individual patient-based meta-analysis, the hazard ratio for reporting abdominal pain with racecadotril vs. placebo was 0.53 [0.34; 0.82] (34).
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of 34  h with a mean frequency of about 7.4 times per day; 
vomiting and dehydration/electrolyte disturbances existed in 
33–36% of patients. Time to cure was the primary endpoint; 
this was 64.3 ±  27.3 h in the control and 33.3 ±  24.0 h in the 
racecadotril group when defined based on frequency of stools, 
70.8 ±  12.8 vs. 47.8 ±  10.5  h when defined based on quality 
of stools and 56.0 ± 16.6 vs. 30.7 ± 14.5 h when defined based 
on presence of dehydration/electrolyte disturbance (Figure  2). 
Accordingly, treatment duration was longer in the control 
than in the racecadotril group (90.9 ±  21.4 vs. 56.8 ±  20.5 h). 
Seventy-two hours after start of treatment, cure was observed 
39/54 patients in the control and 50/55 patients in the racec-
adotril group (70.2 vs. 90.9%).
In summary, the above individual placebo-controlled studies 
as well as the literature-based (35) and the individual patient-
based meta-analyses (34) demonstrate that racecadotril is 
superior to placebo in the treatment of acute diarrhea in adults. 
This was consistent across multiple efficacy parameters includ-
ing duration of diarrhea, number of diarrheic stools, abdominal 
pain, and meteorism (Table 2). Moreover, it was consistent across 
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studies performed in France, Tunisia, and China, likely to repre-
sent different patient populations. From a socio-economic point 
of view, a shortening of sick leave with racecadotril as compared 
to placebo is noteworthy. On the other hand, the tolerability 
was similar to that observed with placebo and, specifically, no 
rebound constipation was observed.
ACTiveLY CONTROLLeD STUDieS 
iN ADULTS
Our search has identified nine studies that compared racecad-
otril to an active control in the treatment of acute diarrhea in 
adults. Seven of them compared racecadotril to loperamide, 
one to the probiotic S. boulardii, and one to the somatostatin 
analog octreotide. The first double-blind study, performed in 
France, randomized 69 patients to receive either racecadotril 
(100  mg; n =  37) or loperamide (1.33  mg; n =  32); in either 
case, two capsules were given at start of treatment, another two 
12 h later, and then one capsule thrice daily until recovery for a 
maximum of 7  days (48). Key inclusion and exclusion criteria 
were similar to the above placebo-controlled studies. The main 
efficacy parameters were time to resolution (2.2 vs. 2.3 days for 
racecadotril and loperamide) and cumulative recovery on day 
2 (59.3 vs. 50.0%; n.s. for both parameters). The percentage of 
patients reporting abdominal pain for more than 1 day also did 
not differ significantly between treatments (40.5% with racecad-
otril vs. 59.4% with loperamide), whereas duration of abdominal 
distension (1.1 vs. 1.8 days) and percentage of patients reporting 
abdominal distension for more than 1 day (40.5 vs. 59.4%) was 
significantly smaller with racecadotril than with loperamide. The 
only reported adverse event, percentage of patients with con-
stipation after resolution of diarrhea was significantly less with 
racecadotril than with loperamide (8.1 vs. 31.3%).
The second double-blind study was also performed in France, 
used similar key inclusion and exclusion criteria and randomized 
157 adults with acute diarrhea but used a slightly different treat-
ment design as compared to the Roge et al. (48) study (49). One 
group of patients received 100 mg racecadotril at start of study, 
followed by thrice daily 100  mg to be taken before each meal 
(n = 82); the other group received 2 mg of loperamide at start 
of study, followed by another 2  mg after each diarrheic stool 
(n =  75). Both treatments were continued until recovery for a 
maximum of 7 days. At inclusion, duration of diarrhea (39.4 vs. 
41.4 h) and number of stools during past 24 h (5.9 vs. 5.3) were 
similar in both groups. Eight patients were withdrawn from the 
study prior to visit 2 (six in racecadotril group including two due 
to lack of efficacy, two due to use of non-permitted concomitant 
medications, one each due to loss to follow-up and withdrawal 
of consent; two in the loperamide group with one each for lack 
of efficacy and withdrawal of consent). Moreover, 5 patients in 
each group failed to fill the evaluation sheets correctly and could 
not be evaluated for efficacy, leaving a total of 77 patients on 
racecadotril and 70 on loperamide for evaluation. The primary 
efficacy endpoint, number of stools passed until recovery, was 
similar for racecadotril and loperamide (3.5 vs. 2.9). Among sec-
ondary efficacy parameters, duration of diarrhea (14.9 vs. 13.7 h) 
and physician’s global evaluation (83.7 vs. 82.3) were also similar 
in both groups. Other efficacy parameters, including asthenia, 
abdominal distension, anorexia, pain on abdominal palpation, 
spontaneous abdominal pain, nausea, anal burning, and vomit-
ing, also exhibited similar frequency in both groups at study 
end. The incidence of adverse events was 7.4% with racecadotril 
and 12% with loperamide, mostly reported as being of mild 
to moderate intensity in both groups. Rebound constipation, 
defined as lack of any stool for at least 2 days during treatment 
and not counted as part of adverse events by the authors, was 
seen in 9.8% of racecadotril as compared to 18.7% of loperamide 
patients; among patients reporting constipation, its duration was 
1.3 days in the racecadotril vs. 1.6 days in the loperamide group.
The third actively controlled study has used a somewhat dif-
ferent design (50). While key exclusion criteria and maximum 
pre-existing duration of diarrhea (up to 5 days) were similar to 
other studies, inclusion required at least three watery stools in the 
past 24 h. While other controlled studies involved various centers 
within 1 country, this study recruited patients from 14 countries 
in Latin America, Africa, and Asia. In a single-blind approach, 
945 patients were randomized to receive 100  mg racecadotril 
(n =  473) or 2  mg loperamide (n =  472) at start of study and 
then thrice daily until resolution of diarrhea (no stool for 12 h or 
two consecutive normal stools) for a maximum of 7 days. Mean 
duration of diarrhea at inclusion was 2.1 days in both groups and 
number of watery stools in the past 24 h was 6.4 and 6.5. The 
primary efficacy parameter was duration of diarrhea, defined as 
time from first dose of study medication to appearance of first 
formed stool, and was 55.0 h in both groups. Recovery rate after 
72 h and overall clinical success (92 vs. 93%) were also similar 
in both groups. Duration of abdominal pain (11.0 vs. 10.0  h) 
was similar in both groups, but duration of abdominal disten-
sion was significantly shorter with racecadotril (5.4 vs. 24.4 h). 
Constipation, defined as at least 36  h without passing a stool, 
occurred less often with racecadotril than with loperamide treat-
ment (16 vs. 25%). Approximately 108 patients reported at least 
one adverse event, with 14.2% in the racecadotril and 23.9% in the 
loperamide group (P = 0.001); similarly, adverse events consid-
ered related to treatment by the investigator occurred in 9 vs. 18% 
of patients. Four patients receiving racecadotril (1  related) and 
10 receiving loperamide (7 related) reported adverse events rated 
as severe by the investigator. Specific adverse events occurring 
significantly less often with racecadotril than with loperamide 
included constipation (as spontaneously reported 3.4 vs. 12.5%), 
enlarged abdomen (1.7 vs. 6.1%), anorexia (0.8 vs. 2.3%), and 
abdominal pain (0.2 vs. 1.9%).
The fourth actively controlled study was performed in Taiwan 
(51) had similar key inclusion and exclusion criteria and study 
design as the Prado and Global Adult Racecadotril Study Group 
(50) study. However, this study randomized 62 patients to single-
blind treatment with either 100  mg racecadotril thrice daily 
or 2 mg loperamide twice daily until recovery for a maximum 
treatment of 7 days. With the limited sample size of 31 patients 
per group, duration of diarrhea (19.5 vs. 13.0 h), of abdominal 
pain (16 vs. 14  h), and of abdominal distension (12 vs. 12  h) 
and improvement rates of anal burn (71.0 vs. 74.2%) and nausea 
(74.2 vs. 77.4%) as well as physician-judged overall clinical suc-
cess (87.1 vs. 87.1%) did not differ significantly between groups 
FigURe 3 | Time course of efficacy (time to resolution of diarrhea) in a 
randomized study comparing loperamide (n = 111) and racecadotril 
(n = 112) based on the intention-to-treat population. Data are shown as 
resolution rates observed at indicated time points (upper panel) and time at 
which a given percentage of patients reported cure (lower panel). Group 
differences did not differ significantly. Drawn based on Hu and Sun (52).
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in the intention-to-treat analysis. Eight patients on racecadotril 
and seven on loperamide reported at least one adverse event; 
however, incidence of constipation was significantly smaller with 
racecadotril than with loperamide (12.9 vs. 29.0%).
The fifth, observer-blinded study, performed in China, 
randomized 223 adults with acute diarrhea to receive 100  mg 
racecadotril or 2  mg loperamide thrice daily until recovery, 
defined as 12  h with no stools or two consecutive normal 
stools, for a maximum of 3  days (52). Twelve patients in the 
racecadotril group (eight due to protocol violation, four due to 
loss of follow-up) and one in the loperamide group (protocol 
deviation) did not complete the study. The primary endpoint 
was time to cure and did not differ significantly between both 
groups in a Kaplan–Meier analysis in the intention-to-treat or 
the per-protocol analysis. Resolution rates at 24, 48, and 72  h 
after initiation of treatment were 65 vs. 61%, 90 vs. 97%, and 
96 vs. 99% in the intention-to-treat analysis in the racecadotril 
and loperamide group, respectively (n.s.; Figure  3). The 25% 
fastest responders had a time to cure of 7  h with racecadotril 
as compared to 5 h with loperamide, the fastest 50% of 16 vs. 
17 h, and the fastest 75% of 32 h in both groups. The percent-
age of patients reporting resolution of specific symptoms with 
racecadotril and loperamide in the intention-to-treat analysis 
did not significantly differ between treatments (91 vs. 85% for 
spontaneous abdominal pain, 89 vs. 92% for pain on abdominal 
palpation, 88 vs. 87% for abdominal distension, 93 vs. 87% for 
anorexia, 98 vs. 100% for nausea, and 96 vs. 100% for anal burn-
ing). In the per-protocol analysis, racecadotril was numerically 
more effective than loperamide for spontaneous abdominal 
pain, pain on abdominal palpation, abdominal distension, and 
anorexia (reach statistical significance for the former three 
symptoms), whereas it was 100% in both groups for nausea 
and anal burning. No patient in either group withdrew due to 
adverse events. Adverse events were reported in 4 patients in the 
racecadotril group (2 with abdominal distension, 1 each with 
abdominal pain or anorexia) and 24 in the loperamide group 
(11 with abdominal distension, 4 with abdominal pain, 3 with 
constipation, 5 with nausea, and 1 with anorexia), of which 4 
and 19, respectively, were judged to be treatment-related by the 
investigator. All adverse events in both groups were classified as 
being of mild to moderate intensity by the investigator.
The sixth, observer-blinded study, performed in India, rand-
omized 120 adults with acute diarrhea to receive either 100 mg 
racecadotril or 2 mg loperamide thrice daily until recovery for a 
maximum of 7 days (53). Five patients in either group withdrew 
from the study (four with adverse events and one with protocol 
deviation in the racecadotril group, two each with adverse events 
or protocol deviation, and one with lack of efficacy in the lop-
eramide group). Eight and six patients in the racecadotril and 
loperamide group, respectively, had protocol deviations, leaving 
52 and 54, respectively, for a per-protocol analysis. The primary 
endpoint was median duration of diarrhea, which was 3 days in 
both groups. Among secondary efficacy endpoints, duration to 
resolution of spontaneous abdominal pain was 1  day each for 
both treatments and 1 vs. 2 days with racecadotril vs. loperamide 
for abdominal distension. Both treatments reduced the preva-
lence of individual symptoms from start of treatment to study 
end (spontaneous abdominal pain: from 77 to 2% for racecadotril 
and 72 to 7% for loperamide; pain on abdominal palpation: from 
48 to 0% and 48 to 3%; abdominal distension: from 23 to 0% 
and 28 to 5%; anorexia: from 27 to 3% and 32 to 5%; nausea: 
38 to 2% and 37 to 5%; anal burning: from 5 to 0% and from 7 
to 2%). Ten patients (16.7%) in the racecadotril (including two 
with constipation, one each with enlarged abdomen, abdominal 
pain, fever, or nausea) and eight (13.3%) in the loperamide group 
(including three with constipation, two with enlarged abdomen, 
and one each with abdominal pain, fever, or nausea) reported 
adverse events. Most of them in either group were judged to be 
of moderate intensity.
The seventh direct comparative trial between racecadotril 
and loperamide was not performed in an outpatient setting as all 
other placebo or actively controlled trials but rather in geriatric 
nursing homes in Italy (54). Sixty-one patients were randomized 
in a double-blind manner to receive 100 mg racecadotril at treat-
ment start and then every 8 h or 2 mg loperamide twice at treat-
ment start and then after each unformed stool with a maximum 
of four tables within 24 h. Treatment was started after the third 
observed diarrhea episode and continued until resolution (two 
consecutive normal stools or no stool for 12 h) for a maximum 
FigURe 4 | Treatment efficacy (time to cure) and tolerability (adverse 
event incidence) of racecadotril in comparison with Saccharomyces 
boulardii [“Saccharomyces.”; (55)]. Data are means of 197 vs. 207 
patients. *P < 0.05 vs. Saccharomyces with no error bar reported by original 
authors, and no statistical analysis reported for tolerability.
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of 4 days. While administration of fluid, specifically standardized 
oral rehydration solution, had not been defined by protocol in the 
above or actively controlled studies, 750 ml of such solution was 
administered daily as base treatment in both groups throughout 
the study. While other studies had involved patients with a mean 
age of about 40  years, participants in this study were about 
82 years of age (range: 73–96). Number of diarrhea episodes after 
start of treatment was 3.93 with racecadotril as compared to 7.29 
with loperamide. In the intention-to-treat population, patients 
treated with racecadotril experienced a significantly shorter 
duration of abdominal pain (14 vs. 28 h) and of diarrhea (36 vs. 
63 h) and less stool output until recovery (120 vs. 150 g/kg). Four 
patients in the loperamide group did not exhibit resolution of 
diarrhea with loperamide, but rapidly recovered after switch to 
racecadotril. At least one adverse event was reported by 12% of 
racecadotril and 60% of loperamide patients. This difference was 
driven by the occurrence of nausea (10 vs. 20%) and constipation 
(15 vs. 60%), whereas other adverse events did not differ between 
groups. Patients not responsive to loperamide were genotyped 
for main allelic variants of CYP 3A4/5 and 2C8; however, neither 
detrimental alleles nor extra copies of functional alleles were 
detected, indicating that they were neither ultra-rapid nor poor 
metabolizers for these two enzymes. In an additional pharma-
coeconomic analysis based on the intention-to-treat population, 
average treatment cost was € 44.85 in the racecadotril and € 91.99 
in the loperamide group.
A meta-analysis on the above seven studies has been reported 
(35). Based on these seven randomized studies with 1618 patients, 
proportion of recovered patients was similar to racecadotril and 
loperamide (hazard ratio 1.08 [0.95; 1.22]). However, a sig-
nificantly lower proportion of patients treated with racecadotril 
reported constipation as compared to those receiving loperamide 
(hazard ratio 0.34 [0.22; 0.51]).
Our search has identified two actively controlled racecadotril 
studies in adults with acute diarrhea, which have used an active 
comparator other than loperamide. One was an investigator-
blinded study performed in Brazil which randomized 334 adults 
to receive either one 100 mg capsule of racecadotril every 8 h 
(n =  175) or two capsules of 100  mg S. boulardii (Floratil®, 
Merck; n  =  161) every 12  h (55). Treatment duration was 
planned until recovery (two consecutive normal bowel move-
ments or no bowel movement for 12  h) for a maximum of 
7  days. Duration of diarrhea prior to start of treatment was 
2.1 vs. 2.0  days, and number of bowel movements in the last 
24 h prior to treatment was 7.0 in both groups. Clinical success 
as judged by the investigator was 96.6% with racecadotril as 
compared to 96.9% with S. boulardii. However, time to recovery 
(64 vs. 77  h; Figure  4) and number of bowel movements per 
24 h until recovery (52 vs. 76 among those with a baseline of 
3–5, 70 vs. 87 among those with 8 or more at baseline) were 
significantly smaller with racecadotril than the probiotic. The 
presence of specific symptoms on day 2 of treatment did not 
differ significantly between groups for spontaneous abdominal 
pain (6.86 vs. 12.42%), pain on abdominal palpation (4.57 vs. 
8.70%), abdominal distension (6.29 vs. 6.21%), anorexia (10.86 
vs. 7.45%), nausea (4.0 vs. 2.48%), or anal burning (1.71 vs. 
2.48%). In a Kaplan–Meier analysis, the estimated probability of 
cure on day 2 was 42% for racecadotril vs. 21% for S. boulardii; 
respective values on day 3 were 67 and 55%; the difference 
between the two treatments was even more pronounced in 
patients with 8 or more bowel movements per day (41 vs. 11%). 
The incidence of adverse events was 6.8% with racecadotril vs. 
7.1% with S. boulardii.
The final direct comparative study was performed in India 
and differed from most other studies in important ways (56). 
First, it included patients with moderate to several acute diar-
rhea of <5  days duration needing hospitalization, i.e., a very 
different patient population. Second, all patients received a 
base treatment of not only fluid substitution but also antibiotics 
(intravenous ciprofloxacin and metronidazole), again suggest-
ing a very different study population. Because of the apparent 
major difference in study population and the lack of a placebo 
arm, we have elected not to include this trial in our analysis of 
placebo-controlled studies. Third, it did not use a fixed dose 
of racecadotril but rather defined target dose based on body 
weight. Fourth, it included as one of the comparator treatments 
the somatostatin analog octreotide, a drug which has mostly 
been studied in diarrhea associated with AIDS or cancer chemo-
therapy (16) and not approved for the treatment of acute diarrhea 
in any major country and, in contrast to all other comparator 
treatments, not available as an over-the-counter medicine 
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requiring subcutaneous injection. This study randomized 150 
patients to receive either fluid substitution plus antibiotics or 
additional racecadotril treatment (1.5  mg/kg) thrice daily or 
additional octreotide treatment (100 μg at time of hospitaliza-
tion). The primary efficacy endpoint was average daily number 
of stools until cure. In the placebo group, this was 12.2 at time 
of admission, 6.8 on day 2, 3.4 on day 3, 2.1 on day 4, and 1.4 on 
day 5. In the racecadotril group, corresponding numbers were 
12.0, 6.7, 3.4, 2.1, and 1.8 (n.s. vs. control for each time point). 
In the octreotide group, these numbers were 14.4, 2.3, and 1.8 
on days 1, 2, and 3, respectively, with no diarrheic stools on days 
4 or 5 (significant vs. control or racecadotril on day 2; Figure 4). 
Averaged daily quantity of stool and required volume of fluid 
substitution showed a similar picture. Unfortunately, the cor-
responding publication does not report any adverse event data.
geNeRAL DiSCUSSiON
Critique of Methods
Unfortunately, many published study reports had limited quality 
as judged by today’s standards. For example, some did not define a 
primary endpoint, did not report on randomization approach, or 
did not mention adverse events. Moreover, with sample sizes of 50 
patients or less per study arm, some studies are likely to have had 
limited power to detect differences between treatments. Finally, 
some studies did not report statistical analysis for the compari-
son of racecadotril vs. comparator treatment. These limitations 
must be considered in the interpretation of the reported study 
outcomes.
Reported clinical studies with racecadotril in the treatment 
of acute diarrhea in adults differ in many ways. First, they have 
been performed in countries in Europe, Africa, Latin America, 
and Asia. These vary considerably in socio-economic status and 
health-care systems. While one of the meta-analyses comparing 
a Tunisian trial with those of “other countries” did not report a 
significant country effect (35), absence of proof is not equivalent 
to proof of absence. Second, allowed duration of diarrhea ranged 
from 3 to 5 days prior to enrollment and maximum treatment 
duration from 3 to 10 days. Third, actively controlled trials have 
involved three different comparator treatments; the treatment 
regimens with the comparator drug loperamide also differed 
between studies. Fourth, studies covered a wide range of sample 
sizes (31–473 per arm), yielding limited statistical power in 
some of them. Fifth, studies used different primary endpoints 
including time to cure, accumulated stool weight, number of 
diarrheic stools, and cumulative recovery on day 2. Finally, it 
is noteworthy that most studies were based on outpatients, but 
one included only geriatric nursing home residents (54) and one 
patients requiring hospital admission and receiving concomitant 
antibiotic treatment (56).
To better understand the efficacy and tolerability of 
racecadotril in the treatment of acute diarrhea in adults, 
two meta-analyses have recently been reported. One of them 
focused on efficacy and analyzed data for both the placebo and 
the loperamide-controlled studies (35). It did not include the 
placebo-controlled study from China (52) but, based on the 
assumption that the efficacy of S. boulardii remains to be proven, 
included the study with this probiotic as active comparator in 
the analysis of placebo-controlled trials. While not including an 
overall analysis of tolerability, it reported on rebound constipa-
tion. The second meta-analysis was overlapping with that by Vetel 
et  al. (35) in some aspects but differed in approach from it in 
several other ways (34). First, similar to Vetel et al. (35), it did 
not include the placebo-controlled Chinese study and, in contrast 
to Vetel et  al., did not include any of the actively controlled 
trials. Second, it used additional parameters for analysis of 
efficacy and tolerability data, including some not mentioned in 
the published articles describing the studies and, accordingly, 
not publicly accessible. Third, its main strength is an analysis 
based on individual patient data; this has allowed the authors to 
include some efficacy and tolerability parameters in the analysis 
that had not been reported in the corresponding publications.
These two meta-analyses (34, 35) provide important quantita-
tive information, and this is their main strength. On the other 
hand, the studies included in these analyses vary considerably 
with regard to country of origin, allowed duration of diarrhea 
prior to inclusion and maximum duration of treatment, chosen 
comparator regimen, sample size, and reported primary outcome 
parameter. Therefore, we have chosen to look at each study the 
way it has been reported. Moreover, we have included a placebo-
controlled study from China that apparently had escaped the 
attention of the previous analyses. We also have considered the 
probiotic S. boulardii as active comparator and, in contrast to 
Vetel et  al. (35) not as equivalent of placebo. Finally, we have 
also included a study comparing racecadotril to octreotide in 
patients with acute diarrhea requiring hospital admission (56). 
Accordingly, we feel that both the meta-analysis approach and 
our more qualitative inspection of study data have merit and 
that they should be seen as complementary.
Comparative efficacy Outcomes
As compared to placebo, racecadotril has proven to exhibit 
greater efficacy. While the studies consistently showed numeri-
cally greater efficacy with racecadotril, this did not reach statisti-
cal significance with small sample sizes in an initial dose-ranging 
study (45). However, two meta-analyses based on aggregated data 
of five studies (35) or on individual patient data of four of these 
studies (34) clearly confirmed the overall efficacy of racecadotril 
as compared to placebo for the endpoint of time to cure (reported 
hazard ratio 1.65 [1.38; 1.97] and 1.80 [1.30; 2.50], respectively). 
These are consistent with the data from an additional placebo-
controlled study not part of these meta-analyses (47). Of note, 
greater efficacy than with placebo was consistent across countries 
and health-care systems [France (46, 57), Tunisia (36), or China 
(52)] and primary study endpoints [duration of diarrhea (31), 
mean stool weight on first day of treatment (36), or number of 
diarrheic stools (46, 47)]. Taken together, these data unequivo-
cally establish racecadotril as an effective treatment of acute 
diarrhea of presumed infectious origin in adults.
Seven studies have directly compared the efficacy of racec-
adotril to that of loperamide. While the six studies based on 
outpatients consistently reported similar efficacy for both treat-
ments, that based on geriatric nursing home residents reported 
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greater efficacy for racecadotril than for loperamide for multiple 
endpoints but had a relatively small sample size (54). Accordingly, 
the hazard ratio for better efficacy assessed as time to cure with 
racecadotril in the meta-analysis of all seven studies was 1.08 
[0.95; 1.22] (35). The comparable efficacy of racecadotril and 
loperamide was consistent across slightly different treatment 
regimens with loperamide. Moreover, similar to the efficacy 
superiority relative to placebo, the efficacy equivalence relative 
to loperamide was consistent across countries and health-care 
systems and primary study endpoints. The only study reporting 
greater efficacy for racecadotril as compared to loperamide for 
duration of diarrhea also reported greater efficacy for several 
other efficacy endpoints including total number of diarrhea 
episodes, total stool output, and duration of abdominal pain (54). 
It also reported pharmacoeconomic superiority of racecadotril 
over loperamide. However, this study is difficult to interpret as 
it had the smallest number of patients per study arm among 
all trials being analyzed here, raising the possibility of random 
effect with small sample size. On the other hand, this study 
differed importantly from the others with regard to included 
patient populations. While other trials had recruited outpatients 
with a mean age of about 40 years, Galleli et al.  (54) included 
elderly patients (range 73–96  years) in a nursing home, i.e., a 
particularly vulnerable population. Whether a possible efficacy 
benefit of racecadotril over loperamide in the elderly truly exists, 
requires independent confirmation of future larger trials.
One randomized study has reported the comparison of 
racecadotril and the probiotic S. boulardii (Floratil®) (55). While 
both treatments achieved “clinical success” as judged by the inves-
tigator in about 97% of patients, time to recovery and number 
of bowel movements per 24 h until recovery were smaller with 
racecadotril. Moreover, probability of cure on day 2 of treatment 
was twice as high with racecadotril as with the probiotic, and an 
even greater difference was found in the subgroup with at least 
eight bowel movements per day at baseline when assessed on 
day 3. On the other hand, individual symptoms assessed on day 
2 (spontaneous abdominal pain, pain on abdominal palpation, 
abdominal distension, anorexia, nausea, and anal burning) did 
not exhibit a consistent pattern of difference; however, with 
overall low incidence of each symptom (<11%), the study was 
clearly underpowered to make such comparisons. Given the lack 
of reliable data on the efficacy of probiotics relative to placebo 
(12, 13), it is difficult to determine whether the difference in the 
latter two parameters reflect the superiority of racecadotril over 
placebo or superiority over an active comparator with weaker 
activity.
The study comparing racecadotril and octreotide showed 
greater efficacy of the latter across multiple endpoints (56). This 
study is the only one recruiting patients with diarrhea requiring 
hospitalization and antibiotic treatment, indicating that it may 
relate to a different patient population. Moreover, data on the 
efficacy and safety of octreotide in the treatment of acute diarrhea 
of presumed infectious origin are sparse (16) and, accordingly, 
octreotide has not been approved for clinical use in such patients 
in any major country. In contrast to all other agents covered 
here, it requires subcutaneous injection. Nevertheless, this 
study raises the intriguing possibility that octreotide may be a 
superior treatment of diarrhea for specific patient groups with 
severe illness, but the identity of such patient groups remains to 
be determined.
Comparative Tolerability Outcomes
The level and granularity of tolerability reporting in studies with 
racecadotril in the treatment of acute diarrhea in adults has been 
heterogeneous. In the placebo-controlled studies, the reported 
adverse events were largely of mild to moderate intensity and 
often reflected symptoms of diarrhea such as nausea and vomit-
ing. The incidence of adverse events was low and comparable 
between placebo- and racecadotril-treated patients. Accordingly, 
one meta-analysis reported that the risk of constipation was 
similar in both groups (relative risk with racecadotril 0.95 [0.24; 
3.68]) with wide confidence intervals reflecting the low overall 
incidence (35). Therefore, both individual studies and meta-
analysis data demonstrate that the tolerability of racecadotril is 
comparable to that of placebo.
A different picture emerged from the actively controlled 
studies, particularly those using loperamide as comparator. 
Thus, patients receiving racecadotril consistently reported a 
lower incidence of adverse events than those receiving lop-
eramide. This difference was largely due to the occurrence of 
constipation after diarrhea had ended, although the definition 
of constipation differed slightly between studies. Accordingly, 
the meta-analysis reported the relative risk of constipation with 
racecadotril as compared to loperamide being 0.34 [0.22; 0.51] 
(35). In patients reporting constipation, its duration was also 
shorter with racecadotril than with loperamide treatment (49). 
Rebound constipation is inconvenient to the patient but perhaps 
even more importantly carries a medical risk due to retention of 
the infectious agent. In a model of newborn gnotobiotic piglets, 
a 4-day treatment with racecadotril (20 mg/kg b.i.d.) was associ-
ated with a similar load of E. coli in proximal jejunum as placebo 
treatment, whereas loperamide (1  mg/kg b.i.d.) treatment was 
associated with a much higher bacterial load (30). While the 
validity of this model has been challenged (58), the effect of 
loperamide in the gnotobiotic piglets is consistent with the effect 
of other opioid receptor agonists in a rat model of intestinal bacte-
rial load (59). Moreover, in experimental studies, both in rats 
(racecadotril 40 mg/kg orally) and mice (racecadotril or its active 
metabolite thiorphan 20 mg/kg i.v.) did not affect gastrointestinal 
transit, whereas loperamide (2  mg/kg orally in rats, 0.5  mg/kg 
i.v. in mice) did (27). Accordingly, racecadotril treatment for 
up to 1  week did not modify oro-coecal, colonic, or overall 
gastrointestinal transit times (28, 29), whereas prolongation of 
gastrointestinal transit time and occurrence of constipation are 
recognized effects of loperamide (9). Therefore, the US Food 
and Drug Administration considers bacterial enterocolitis caused 
by invasive microorganisms including Salmonella, Shigella, and 
Campylobacter and pseudomembranous colitis associated with 
the use of broad-spectrum antibiotics to be a contraindication 
for use of loperamide (9).
Other adverse events, such as enlarged abdomen, anorexia, 
and abdominal pain, were also less frequent with racecadotril 
in a study with large sample size (50). The difference in adverse 
event incidence between the two groups was largest in the study 
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in elderly patients (12 vs. 60%) (54). In contrast, the incidence 
of adverse events was similar and low in the comparison of 
racecadotril and the probiotic S. boulardii (55). The comparison 
of racecadotril and octreotide did not report adverse event 
data (56).
Conclusion
In summary, racecadotril exhibited greater efficacy but similar 
tolerability as compared to placebo or the probiotic S. boulardii. In 
contrast, racecadotril had similar efficacy but greater tolerability, 
particularly less constipation and abdominal discomfort, as com-
pared to loperamide; in an elderly population, racecadotril may 
have greater efficacy and better tolerability than loperamide. The 
occurrence of secondary constipation upon treatment of acute 
diarrhea is not only a matter of quality of life; rather, it may have 
medical consequences because of retention of infectious agent.
Apart from effects on gastrointestinal transit and constipation, 
other aspects also differentiate racecadotril and loperamide. Thus, 
loperamide metabolism involves CYP enzymes CYP 2C8 and 
3A4 and is a substrate for P-glycoprotein, and inhibitors of these 
enzymes and transporter inhibit its elimination and increase 
its plasma levels upon co-administration (9). Such drug–drug 
interactions may also carry a risk of serious heart problems 
(11). In contrast, inactivation and elimination of racecadotril 
is not subject to such drug–drug interactions (22). Moreover, 
prescribing information warns to apply special caution in the use 
of loperamide in young children (9). Similarly, a guideline of the 
World Gastroenterology Association states that loperamide “is 
not recommended for use in children <2 years” (2). In contrast, 
racecadotril is registered and used in children starting at an age 
of 3 months.
The above limitations notwithstanding, loperamide is an 
effective and safe medication for the treatment of acute diarrhea 
of presumed infectious origin as long as the existing contrain-
dications are observed. Therefore, loperamide is available as an 
over-the-counter medication in many countries. Racecadotril is 
also available as over-the-counter medication in many countries. 
As medication safety is a key criterion for the use of such non-
prescription treatments, the consistently observed tolerability 
benefit of racecadotril over loperamide despite comparable 
efficacy should favor its use, particularly as over-the-counter 
medication.
While the above studies clearly define a role for racecadotril 
in the treatment of acute diarrhea in adults relative to placebo 
or to loperamide, they also point to three relevant directions for 
future research in this area. First, the study reporting a much 
greater efficacy with racecadotril as compared to loperamide is 
the only one performed in a geriatric population in a nursing 
home setting (54). However, it also had the smallest sample size 
among the studies discussed here. As the elderly are particularly 
vulnerable to diarrhea-induced dehydration, additional data in 
elderly populations are required to derive treatment recommen-
dations in this patient group. Second, probiotics are a guideline-
recommended treatment for acute diarrhea, particularly in 
children, these recommendations have been criticized because of 
limited strength of the underlying data with regard to methodol-
ogy and sample sizes (12–14). Only with more clarity on the value 
of probiotics in the treatment of acute diarrhea in adults, one can 
place the reported benefit of racecadotril over S. boulardii (55) in 
perspective. Finally, one report has suggested that octreotide may 
be more effective than racecadotril (56) but is based on a patient 
population differing considerably from those in all other studies. 
Specifically, Mehta et  al. (56) have studied patients with such 
severe diarrhea that hospitalization and concomitant antibiotic 
treatment were required. Moreover, that study unfortunately 
has not reported on adverse events observed with the two treat-
ments. Additional studies will be required to define the benefit/
risk ratios of octreotide and racecadotril in patients with severe 
diarrhea requiring hospitalization.
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